Athena Health has jumped nicely since you wrote your stock warning in August. It recently reached as high as $167 on Nov 23. and has proven itself as a company that has outperformed on earnings. Curious to know if you still think it should be avoided?
Like many major consumer goods purchases, people will tend to buy less during an economic downturn and car sales are a pretty good bellwether of the economy. Almost exactly seven years ago, on Dec 1st 2008, Ford hit a low point of $1.50 during the last recession. It since leaped back up to a high of 17.41 on May 31, 2014. It took a while to get there but it did bounce back. How people must have been kicking themselves for selling in 2008.
Whatever you do, it would be wise to not sell stocks by trying to time the market. We might already be in a global economic decline but its important to remember stocks will always rise and fall. Bite the bullet, and do not fear as stocks take a hit with the ever more probable downturn. Wait for stocks to drop 50% then buy buy buy!
This is one of those drugs that could potentially have a tremendous impact on saving lives in the US and globally. The Center for Disease Control stated the following based on a 2011 study: the annual burden of Clostridium difficile infections in the United States, is 453,000 cases per year, with 29,300 associated deaths. If Synthetic Biologics can successfully bring this drug to market, the stock is likely to climb much higher.
CBOE isn't exactly a stellar performer this past year, only up 1.3% and out of 12 analyst opinions only 2 recommend it as a good buy while 10 recommend holding.The stock closed down 2.99% by end of trading yesterday (December 9). Athena Health is up over 10% YTD and yesterday topped earnings estimates.Athena should continue to grow as healthcare is a hot sector service sector in the US and it's products and services are in high demand. The stock is up almost 300% in the past 5 years! Amazon is one of the darlings of all stocks loved by analysts and investors alike. This month out of 38 analysts, 13 are a strong buy, 23 are a buy and 5 are a hold. With major holiday buying season about to begin look out for blockbuster earnings results to boost the stock yet further.
Since you wrote this article last April, Buffett bought a massive amount of shares in Philips 66 (PSX) the oil refining company. Oil refining companies have benefited by the drop in oil prices and so are the logical place to invest when oil is crashing. In the last six months, PSX is up over 16%. Buffett seems to know what he was doing, he bought the stock for around $75 in late August this year, it is now around $93. PSX has a low P/E of 10.8, and an annual dividend of 2.4%.
Hi again, just checking in. So it seems the situation for oil since June has continued to decline and along with it the well being of SDLP and companies like it. Since June the stock is nosedived over 40% and that attractive dividend that I spoke about last time, well its now up to 24% but honestly when one loses going on for half the value of an investment even a juicy dividend isn't going to soften the blow. The problem is that when a stock loses so much value it rarely bounces back to the pre-collapse levels. SDLP would not have been a safe investment in June. The place to stack money was or probbaly still is in oil refinery stocks. I particularly like PSX (Philips 66) which in the same 6 month period is UP over 16%. If in doubt, follow the Buffett! He bought the stock for around $75 in late August this year. PSX has a low P/E of 10.8, and an annual dividend of 2.4%
With the high level of volatility in healthcare and biotech stocks. Don't try to cherry pick, I still like IBB as a safer investment choice. It has some of the biggest companies as part of its portfolio but spreads the risk by not over allocating in any one company. Its top four allocations (by percentage allocation) are:
Amgen Inc. 8.76%, Celgene Corp. 8.73%, Regeneron Pharm. 8.69 % Gilead Sciences 8.65% and Biogen 8.21%.
Year to date, it has returned 7.31% but over 5 years it has returned 279%. Now obviously there will good and bad years but I think this ETF is one to hold for the long hall.
The market didn't seem to like the idea of this massive all stock purchase merger announcement yesterday. Both stocks dropped on the news. Pfizer closed down 2.6% and Allergan dropped around 3.4% in trading yesterday.
In comparing these two giants, PFE has a rewarding dividend of 3.48% to soften the blow in the short term. AGN has a market cap of almost $119.92 billion versus PFE's market cap of $193.4 billion.
Two beneficiaries of this merger are Teva that will be taking over the remaining generic drug sector from AGN as part of the deal, and the Irish economy that will reap considerable tax revenues from the relocation of Pfizer on to its soil.
Latest Comments
New Stocks On Most Attractive And Most Dangerous Lists: August 2015
Athena Health has jumped nicely since you wrote your stock warning in August. It recently reached as high as $167 on Nov 23. and has proven itself as a company that has outperformed on earnings. Curious to know if you still think it should be avoided?
This Sector’s About To Be Turned On Its Head
Like many major consumer goods purchases, people will tend to buy less during an economic downturn and car sales are a pretty good bellwether of the economy. Almost exactly seven years ago, on Dec 1st 2008, Ford hit a low point of $1.50 during the last recession. It since leaped back up to a high of 17.41 on May 31, 2014. It took a while to get there but it did bounce back. How people must have been kicking themselves for selling in 2008.
Retail Reality: Another Sign A Recession And Crash Are Imminent
Whatever you do, it would be wise to not sell stocks by trying to time the market. We might already be in a global economic decline but its important to remember stocks will always rise and fall. Bite the bullet, and do not fear as stocks take a hit with the ever more probable downturn. Wait for stocks to drop 50% then buy buy buy!
Synthetic Biologics Announces Positive Phase 2 Results For Prevention Of Bacterial Infection
This is one of those drugs that could potentially have a tremendous impact on saving lives in the US and globally. The Center for Disease Control stated the following based on a 2011 study: the annual burden of Clostridium difficile infections in the United States, is 453,000 cases per year, with 29,300 associated deaths. If Synthetic Biologics can successfully bring this drug to market, the stock is likely to climb much higher.
5 Very Persistent Winners
CBOE isn't exactly a stellar performer this past year, only up 1.3% and out of 12 analyst opinions only 2 recommend it as a good buy while 10 recommend holding.The stock closed down 2.99% by end of trading yesterday (December 9). Athena Health is up over 10% YTD and yesterday topped earnings estimates.Athena should continue to grow as healthcare is a hot sector service sector in the US and it's products and services are in high demand. The stock is up almost 300% in the past 5 years! Amazon is one of the darlings of all stocks loved by analysts and investors alike. This month out of 38 analysts, 13 are a strong buy, 23 are a buy and 5 are a hold. With major holiday buying season about to begin look out for blockbuster earnings results to boost the stock yet further.
Oil Jobs Lost: 250.000 And Counting, Texas Likely To See Massive Layoffs Soon
I wonder if these folks will be re-employed if and when oil demand bounces back and oil prices go back to a more normal level.
Is Warren Buffett Wrong About Oil Stocks?
Since you wrote this article last April, Buffett bought a massive amount of shares in Philips 66 (PSX) the oil refining company. Oil refining companies have benefited by the drop in oil prices and so are the logical place to invest when oil is crashing. In the last six months, PSX is up over 16%. Buffett seems to know what he was doing, he bought the stock for around $75 in late August this year, it is now around $93. PSX has a low P/E of 10.8, and an annual dividend of 2.4%.
Seadrill Partners Could Offer An Intriguing High-Yield Opportunity
Hi again, just checking in. So it seems the situation for oil since June has continued to decline and along with it the well being of SDLP and companies like it. Since June the stock is nosedived over 40% and that attractive dividend that I spoke about last time, well its now up to 24% but honestly when one loses going on for half the value of an investment even a juicy dividend isn't going to soften the blow. The problem is that when a stock loses so much value it rarely bounces back to the pre-collapse levels. SDLP would not have been a safe investment in June. The place to stack money was or probbaly still is in oil refinery stocks. I particularly like PSX (Philips 66) which in the same 6 month period is UP over 16%. If in doubt, follow the Buffett! He bought the stock for around $75 in late August this year. PSX has a low P/E of 10.8, and an annual dividend of 2.4%
Large Cap Biotech Stocks Get Traction From Revenue Growth
With the high level of volatility in healthcare and biotech stocks. Don't try to cherry pick, I still like IBB as a safer investment choice. It has some of the biggest companies as part of its portfolio but spreads the risk by not over allocating in any one company. Its top four allocations (by percentage allocation) are:
Amgen Inc. 8.76%, Celgene Corp. 8.73%, Regeneron Pharm. 8.69 % Gilead Sciences 8.65% and Biogen 8.21%.
Year to date, it has returned 7.31% but over 5 years it has returned 279%. Now obviously there will good and bad years but I think this ETF is one to hold for the long hall.
Pfizer Merges With Allergan In $150 Billion Deal
The market didn't seem to like the idea of this massive all stock purchase merger announcement yesterday. Both stocks dropped on the news. Pfizer closed down 2.6% and Allergan dropped around 3.4% in trading yesterday.
In comparing these two giants, PFE has a rewarding dividend of 3.48% to soften the blow in the short term. AGN has a market cap of almost $119.92 billion versus PFE's market cap of $193.4 billion.
Two beneficiaries of this merger are Teva that will be taking over the remaining generic drug sector from AGN as part of the deal, and the Irish economy that will reap considerable tax revenues from the relocation of Pfizer on to its soil.